Insider · CIK 0001852291
Wang Lai
officer
Files at ONC (BeOne Medicines Ltd.). First filing Feb 25, 2025, latest Feb 25, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $1.3M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 55Moderate | sell 610b5-1 | ONC BeOne Medicines Ltd. | $1.3M | 5,000 | -100% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | ONC BeOne Medicines Ltd. | AGrant or award Ordinary Shares | +69,251 | $0.00 | $0 | 990,171 | Mar 7, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,327 | $254.82 | $338k | 3,673 | Feb 25, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -575 | $255.86 | $147k | 3,098 | Feb 25, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -479 | $256.70 | $123k | 2,619 | Feb 25, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -437 | $258.18 | $113k | 2,182 | Feb 25, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -1,782 | $258.73 | $461k | 400 | Feb 25, 2025 |
| Feb 21, 2025 | ONC BeOne Medicines Ltd. | SOpen-market sale American Depositary Sharesindirect: See Footnote10b5-1 | -400 | $260.17 | $104k | 0 | Feb 25, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.